Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson Sells 11,447 Shares

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 11,447 shares of the business’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $7.64, for a total value of $87,455.08. Following the sale, the director now directly owns 7,066,113 shares of the company’s stock, valued at $53,985,103.32. This represents a 0.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, October 29th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $6.72, for a total transaction of $76,923.84.
• On Tuesday, October 15th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $6.67, for a total transaction of $76,351.49.
• On Tuesday, October 1st, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $6.22, for a total transaction of $71,200.34.
• On Tuesday, September 17th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $6.84, for a total value of $78,297.48.
• On Tuesday, September 3rd, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $6.27, for a total value of $71,772.69.
• On Tuesday, August 20th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $7.12, for a total value of $81,502.64.

Recursion Pharmaceuticals Stock Down 7.8 %

Shares of RXRX traded down $0.54 during mid-day trading on Friday, hitting $6.37. 2,818,972 shares of the company’s stock were exchanged, compared to its average volume of 5,717,881. The company has a 50-day simple moving average of $6.65 and a 200 day simple moving average of $7.61. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The company has a market cap of $1.79 billion, a PE ratio of -4.18 and a beta of 0.81. Recursion Pharmaceuticals, Inc. has a 52 week low of $5.89 and a 52 week high of $15.74.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The company had revenue of $26.08 million for the quarter, compared to the consensus estimate of $12.62 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business’s revenue was up 147.6% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.43) EPS. On average, research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.56 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. ARK Investment Management LLC raised its stake in Recursion Pharmaceuticals by 16.4% in the 3rd quarter. ARK Investment Management LLC now owns 32,769,186 shares of the company’s stock valued at $215,949,000 after acquiring an additional 4,626,268 shares during the period. Baillie Gifford & Co. increased its holdings in shares of Recursion Pharmaceuticals by 10.5% in the second quarter. Baillie Gifford & Co. now owns 26,589,936 shares of the company’s stock valued at $199,425,000 after purchasing an additional 2,522,132 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Recursion Pharmaceuticals by 2.2% in the first quarter. Vanguard Group Inc. now owns 16,014,764 shares of the company’s stock valued at $159,667,000 after purchasing an additional 349,554 shares during the period. Kinnevik AB publ lifted its stake in shares of Recursion Pharmaceuticals by 14.4% during the 2nd quarter. Kinnevik AB publ now owns 11,905,668 shares of the company’s stock worth $89,293,000 after buying an additional 1,500,000 shares during the last quarter. Finally, FMR LLC boosted its holdings in shares of Recursion Pharmaceuticals by 2.1% during the 3rd quarter. FMR LLC now owns 8,363,530 shares of the company’s stock worth $55,116,000 after buying an additional 170,810 shares during the period. Institutional investors own 89.06% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on RXRX. Needham & Company LLC restated a “buy” rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a report on Thursday, November 7th. Jefferies Financial Group dropped their price objective on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research note on Tuesday, September 3rd. Finally, Leerink Partners lowered their target price on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research note on Tuesday, September 3rd. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $9.25.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.